Want to see PRGO full AI Analyst Report?
PRGO Stock Chart & Stats
$10.09
$0.27(2.68%)
At close: 4:00 PM EDT
$10.09
$0.27(2.68%)
Day’s Range― - ―
52-Week Range$9.23 - $24.61
Previous CloseN/A
Volume1.22M
Average Volume (3M)3.63M
Market Cap
$1.90B
Enterprise Value$4.45K
Total Cash (Recent Filing)$399.70M
Total Debt (Recent Filing)$3.29B
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 11, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield8.14%
Share Statistics
EPS (TTM)-12.51
Shares Outstanding138,769,240
10 Day Avg. Volume2,634,189
30 Day Avg. Volume3,634,402
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.45
P/FCF Ratio13.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.00Price Target Upside68.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.14
Revenue Forecast (FY)$4.05B
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive operating and free cash flow provides durable internal funding for dividends, capex, and debt reduction even while accounting earnings are weak. This cash-generation capacity supports strategic flexibility and funds the operational enhancement program without relying solely on external financing.
Operational Execution & Share GainsMaterial improvements in service levels and execution strengthen retailer relationships and shelf availability, which are durable advantages in private-label OTC. Consistent service gains and modest market share growth in the U.S. and Europe improve competitive positioning and support more stable revenue capture over multiple quarters.
Portfolio Simplification And Debt ReductionThe deliberate portfolio simplification and use of divestiture proceeds to pay down borrowings materially reduce structural leverage risk and allow management to focus on core self-care categories. Preserving capital discipline via targeted sales enhances long-term balance-sheet resilience and strategic clarity.
Bears Say
Revenue Decline & LossesA sustained decline in revenue combined with material operating and net losses signals durable execution and demand challenges. Shrinking top line constrains operating leverage, limits reinvestment capacity, and increases the reliance on nonrecurring actions to restore profitability over the coming quarters.
Elevated LeverageLeverage materially above parity despite recent reductions leaves the company exposed to interest and refinancing risk and reduces financial flexibility. With profitability weak, servicing elevated debt limits the ability to fund investment and increases sensitivity to adverse demand or cost shocks over the medium term.
Margin Pressure & Under-absorptionSustained gross margin compression and a sizable planned under-absorption EPS headwind reflect structural volume shortfalls and cost absorption challenges. Even with cost programs, these factors materially erode earnings power and make near-term margin recovery dependent on durable volume growth and execution improvements.
Perrigo Company News
PRGO FAQ
What was Perrigo Company’s price range in the past 12 months?
Perrigo Company lowest stock price was $9.22 and its highest was $24.61 in the past 12 months.
What is Perrigo Company’s market cap?
Perrigo Company’s market cap is $1.90B.
When is Perrigo Company’s upcoming earnings report date?
Perrigo Company’s upcoming earnings report date is Nov 11, 2026 which is in 81 days.
How were Perrigo Company’s earnings last quarter?
Perrigo Company released its earnings results on Aug 05, 2026. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.388 by $0.112.
Is Perrigo Company overvalued?
According to Wall Street analysts Perrigo Company’s price is currently Undervalued.
Does Perrigo Company pay dividends?
Perrigo Company pays a Quarterly dividend of $0.29 which represents an annual dividend yield of 8.14%. See more information on Perrigo Company dividends here
What is Perrigo Company’s EPS estimate?
Perrigo Company’s EPS estimate is 0.52.
How many shares outstanding does Perrigo Company have?
Perrigo Company has 138,769,240 shares outstanding.
What happened to Perrigo Company’s price movement after its last earnings report?
Perrigo Company reported an EPS of $0.5 in its last earnings report, beating expectations of $0.388. Following the earnings report the stock price went up 23.098%.
Which hedge fund is a major shareholder of Perrigo Company?
Currently, no hedge funds are holding shares in PRGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perrigo Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (68.48% Upside)
$17.00 (68.48% Upside)
Blogger Sentiment
Bullish
PRGO Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.03%
12-Months-Change
Fundamentals
Return on Equity
8.14%
Trailing 12-Months
Asset Growth
-24.61%
Trailing 12-Months
Company Description
Perrigo Company
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
PRGO Company Deck
PRGO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational progress and strategic actions against ongoing top-line and margin pressures. Positive indicators include market share gains, substantial service-level improvements, a recovering Infant Formula business (+23% sales, +$60M operating income), acceleration of a scalable innovation pipeline, targeted cost-savings ($80–$100M program) and the use of $359M divestiture proceeds to reduce debt. Offsetting these positives were a 3%+ decline in net sales, 250 basis points of gross margin compression, notable retailer destocking (≈1.8% headwind), specialty segment weakness and an expected ~$0.60 EPS headwind in 2026 from under-absorption. Management maintained full-year guidance and emphasized that results are weighted to a stronger second half, signaling cautious optimism but acknowledging remaining execution and demand risks.View all PRGO earnings summariesPRGO Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$17.00
▲(68.48% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Viatris
―
Supernus Pharmaceuticals
―
Teva Pharmaceutical
―
Indivior
―
Amneal Pharmaceuticals
―
Ownership Overview
0.38% Insiders
29.54% Mutual Funds
25.05% Other Institutional Investors
2.98% Public Companies and
Individual Investors








